Condition: Renal Cancer · Metastases · PSMA PET · Sponsor: Xijing Hospital
The primary research purpose is to evaluate the diagnostic efficacy of 68Ga-PSMA PET in metastatic lesions of locally advanced and advanced renal cell carcinoma, and to compare with that of enhanced CT. The second purpose is to evaluate whether 68Ga-PSMA PET can change the treatment decision of patients with locally advanced and advanced renal cell carcinoma
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| The First Hospital of Lanzhou University | Lanzhou, Gansu, China | Recruiting |
| General Hospital of Ningxia Medical University | Yinchuan, Ningxia, China | Recruiting |
| Qinghai University Affiliated Hospital | Xining, Qinghai, China | Recruiting |
| Xijing Hospital | Xi'an, Shaan'xi, China | Recruiting |
| Weinan Central Hospital | Weinan, Shaanxi, China | Recruiting |
| Shaanxi Provincial People's Hospital | Xi'an, Shaanxi, China | Recruiting |
| Xijing 986 Hospital | Xi'an, Shaanxi, China | Recruiting |
| The Second Affiliated Hospital of Shaanxi University of Chinese Medicine | Xianyang, Shaanxi, China | Recruiting |
| Affiliated Hospital of Yan'an University | Yan’an, Shaanxi, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04987086